In this study, we aimed to evaluate the efficacy of a synthetic retinoid, Nevrargenics’ lead drug, Ellorarxine (also known as DC645 and NVG0645), an RAR-modulator, on ALS in vitro. This evidence concerns the gene RARA and amyotrophic lateral sclerosis.